Nonmyeloablative allografting for newly diagnosed

Nonmyeloablative allografting for newly diagnosed
multiple myeloma: the experience of the Gruppo Italiano
Trapianti di Midollo
by Benedetto Bruno, Marcello Rotta, Francesca Patriarca, Daniele Mattei,
Bernardino Allione, Fabrizio Carnevale-Schianca, Roberto Sorasio, Alessandro
Rambaldi, Marco Casini, Matteo Parma, Pasqua Bavaro, Francesco Onida,
Alessandro Busca, Luca Castagna, Edoardo Benedetti, Anna Paola Iori, Luisa
Giaccone, Antonio Palumbo, Paolo Corradini, Renato Fanin, David Maloney, Rainer
Storb, Ileana Baldi, Umberto Ricardi, and Mario Boccadoro
Blood
Volume 113(14):3375-3382
April 2, 2009
©2009 by American Society of Hematology
Cumulative incidence estimates of GVHD and mortality.
Benedetto Bruno et al. Blood 2009;113:3375-3382
©2009 by American Society of Hematology
Kaplan-Meier estimates of OS and EFS after a follow up of 5 years.
Benedetto Bruno et al. Blood 2009;113:3375-3382
©2009 by American Society of Hematology
Clinical outcome.
Benedetto Bruno et al. Blood 2009;113:3375-3382
©2009 by American Society of Hematology
Clinical outcome.
Benedetto Bruno et al. Blood 2009;113:3375-3382
©2009 by American Society of Hematology